Compare Abbott Laboratories (ABT) vs American Homes 4 Rent Class A (AMH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs American Homes 4 Rent Class A — how do they compare? Abbott Laboratories trades at $109.32 (market cap $187.95B), while American Homes 4 Rent Class A trades at $33.7 (market cap $12.28B). The key difference: Abbott Laboratories is far larger — about 15.3× American Homes 4 Rent Class A's market cap, and American Homes 4 Rent Class A pays the higher dividend (3.87%). Which is the better fit depends on your goals.
| ABT | AMH | |
|---|---|---|
Market Cap | $187.95B | $12.28B |
Sector | Health | Real Estate |
52-Week High | $136.62 | $35.82 |
52-Week Low | $82.57 | $27.38 |
Enterprise Value | $214.96B | $17.35B |
Dividend Yield | 2.32% | 3.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
AMH trades at $34.13, down 1.44% on the day, with a bullish technical signal from moving averages and a consensus price target of $36.45. The company reported strong Q2 2026 earnings, beating FFO and revenue estimates, and raised full-year guidance. Revenue grew to $1.85B in 2025, with net income margin improving to 25.53%. A dividend of $0.33 per share is scheduled for payment on June 30, 2026.
Outlook is positive with consistent earnings beats and raised guidance, but risks include high debt levels and regulatory impacts from new housing legislation. Institutional sentiment remains supportive with no sell ratings among analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About American Homes 4 Rent Class A
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas
Read more on AMH →
